Julia Angeles

In this discussion, Julia Angeles, an investment manager at Baillie Gifford, shares insights about Argenx, a $30 billion immunology company known for utilizing llama antibodies in drug development. They explore how Argenx navigates the complexities of drug trials and regulatory hurdles while focusing on innovative therapies for autoimmune diseases. Julia emphasizes the importance of patient outcomes and cultural resilience within biotech, as well as the company’s remarkable growth and future potential in the market.